Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.

Serie DJ, Joseph RW, Cheville JC, Ho TH, Parasramka M, Hilton T, Thompson RH, Leibovich BC, Parker AS, Eckel-Passow JE.

Eur Urol. 2016 Nov 26. pii: S0302-2838(16)30851-X. doi: 10.1016/j.eururo.2016.11.018. [Epub ahead of print]

PMID:
27899233
2.

Whole-exome sequencing of a family with local anesthetic resistance.

Clendenen N, Cannon AD, Porter S, Robards CB, Parker AS, Clendenen SR.

Minerva Anestesiol. 2016 Oct;82(10):1089-1097.

PMID:
27243970
3.

Contrast-induced nephropathy in outpatients with preexisting renal impairment: a comparison between intravenous iohexol and iodixanol.

Cernigliaro JG, Haley WE, Adolphson DP, Jepperson MA, Crook JE, Thomas CS, Parker AS.

Clin Imaging. 2016 Sep-Oct;40(5):902-6. doi: 10.1016/j.clinimag.2016.04.008.

PMID:
27183138
4.

An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer.

Heckman MG, Robinson JL, Tzou KS, Parker AS, Wu KJ, Hilton TW, Howat WJ, Miller JL, Kreinest PA, Pisansky TM, Schild SE, Peterson JL, Vallow LA, Carroll JS, Buskirk SJ.

PLoS One. 2016 Mar 17;11(3):e0151785. doi: 10.1371/journal.pone.0151785.

5.

Author Reply.

Thiel DD, Davidiuk AJ, Meschia C, Serie D, Custer K, Petrou SP, Parker AS.

Urology. 2016 Mar;89:61-2. doi: 10.1016/j.urology.2015.10.039. No abstract available.

PMID:
26797576
6.

Radical Prostatectomy Trends in the United States: 1998 to 2011.

Tyson MD 2nd, Andrews PE, Ferrigni RF, Humphreys MR, Parker AS, Castle EP.

Mayo Clin Proc. 2016 Jan;91(1):10-6. doi: 10.1016/j.mayocp.2015.09.018.

PMID:
26763510
7.

Mayo Adhesive Probability Score Is Associated With Localized Renal Cell Carcinoma Progression-free Survival.

Thiel DD, Davidiuk AJ, Meschia C, Serie D, Custer K, Petrou SP, Parker AS.

Urology. 2016 Mar;89:54-60. doi: 10.1016/j.urology.2015.10.034.

PMID:
26723183
8.

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.

Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Tong P, Wang J, Castle EP, Stanton ML, Cheville JC, Jonasch E, Brugarolas J, Parker AS.

Mod Pathol. 2016 Jan;29(1):34-42. doi: 10.1038/modpathol.2015.123.

9.

Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.

Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, Frenkel E, Parker AS, Brugarolas J.

J Urol. 2016 Jan;195(1):180-7. doi: 10.1016/j.juro.2015.07.113.

PMID:
26300218
10.

A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona.

Ho TH, Nateras RN, Yan H, Park JG, Jensen S, Borges C, Lee JH, Champion MD, Tibes R, Bryce AH, Carballido EM, Todd MA, Joseph RW, Wong WW, Parker AS, Stanton ML, Castle EP.

PLoS One. 2015 Jul 16;10(7):e0132831. doi: 10.1371/journal.pone.0132831.

11.

Comparison of patient-reported quality of life outcome questionnaire response rates between patients treated surgically for renal cell carcinoma and prostate carcinoma.

Thiel DD, Davidiuk AJ, Broderick GA, Arnold M, Diehl N, Tavlarides A, Custer K, Parker AS.

BMC Urol. 2015 Jul 1;15:58. doi: 10.1186/s12894-015-0057-y.

12.

Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature.

Gupta E, Guthrie KJ, Krishna M, Asmann Y, Parker AS, Joseph RW.

Rare Tumors. 2015 Feb 25;7(1):5719. doi: 10.4081/rt.2015.5719.

13.

Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer.

Wu L, Chaffee KG, Parker AS, Sicotte H, Petersen GM.

Tumour Biol. 2015 Sep;36(10):7431-7. doi: 10.1007/s13277-015-3459-2.

14.

Prospective evaluation of the association of adherent perinephric fat with perioperative outcomes of robotic-assisted partial nephrectomy.

Davidiuk AJ, Parker AS, Thomas CS, Heckman MG, Custer K, Thiel DD.

Urology. 2015 Apr;85(4):836-42. doi: 10.1016/j.urology.2014.12.017.

PMID:
25669734
15.

Whole-exome sequencing as a diagnostic tool in a family with episodic ataxia type 1.

Tacik P, Guthrie KJ, Strongosky AJ, Broderick DF, Riegert-Johnson DL, Tang S, El-Khechen D, Parker AS, Ross OA, Wszolek ZK.

Mayo Clin Proc. 2015 Mar;90(3):366-71. doi: 10.1016/j.mayocp.2015.01.001.

16.

Comment on: the incidence and risk factors of metastasis for cutaneous squamous cell carcinoma--implications on the T-classification system.

Jambusaria-Pahlajani A, Karia PS, Parker AS, Schmults CD.

J Surg Oncol. 2015 Mar 15;111(4):483-4. doi: 10.1002/jso.23841. No abstract available.

PMID:
25492622
17.

Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.

Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Parasramka M, Cheville JC, Wu KJ, Frenkel E, Rakheja D, Stefanius K, Brugarolas J, Parker AS.

Urol Oncol. 2015 Jan;33(1):23.e9-14. doi: 10.1016/j.urolonc.2014.10.014.

18.

Mayo adhesive probability score: an accurate image-based scoring system to predict adherent perinephric fat in partial nephrectomy.

Davidiuk AJ, Parker AS, Thomas CS, Leibovich BC, Castle EP, Heckman MG, Custer K, Thiel DD.

Eur Urol. 2014 Dec;66(6):1165-71. doi: 10.1016/j.eururo.2014.08.054.

PMID:
25192968
19.

Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis.

Eckel-Passow JE, Igel DA, Serie DJ, Joseph RW, Ho TH, Cheville JC, Parker AS.

Urol Oncol. 2015 Feb;33(2):68.e17-23. doi: 10.1016/j.urolonc.2014.07.019.

PMID:
25175426
20.

Baseline and follow-up association of the MAX-PC in Men with newly diagnosed prostate cancer.

Tavlarides AM, Ames SC, Thiel DD, Diehl NN, Parker AS.

Psychooncology. 2015 Apr;24(4):451-7. doi: 10.1002/pon.3605.

Items per page

Supplemental Content

Loading ...
Support Center